KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Cash & Current Investments (2009 - 2026)

Bristol Myers Squibb (BMY) reported Cash & Current Investments of $10.5 billion for Q1 2026, down 11.0% year-over-year from $11.8 billion in Q1 2025, and down 1.75% on a QoQ basis from $10.7 billion in Q4 2025.

Bristol Myers Squibb (BMY) has 18 years of Cash & Current Investments data on file, last reported at $10.5 billion in Q1 2026.

  • Quarterly Cash & Current Investments fell 11.0% year-over-year to $10.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 billion (down 11.0% YoY) and the FY2025 annual result came in at $10.7 billion, down 1.71% from the prior year.
  • Cash & Current Investments slipped to $10.5 billion in Q1 2026 per BMY's latest filing, from $10.7 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $16.5 billion in Q3 2025 and bottomed at $6.7 billion in Q2 2024.
  • The 5-year median for Cash & Current Investments is $10.5 billion (2026), against an average of $10.8 billion.
  • The widest annual swing landed in 2022, when Cash & Current Investments plunged 45.46%; it then soared 104.46% in 2025.
  • Tracing BMY's Cash & Current Investments over 5 years: stood at $9.3 billion in 2022, then soared by 32.71% to $12.3 billion in 2023, then retreated by 11.57% to $10.9 billion in 2024, then slipped by 1.71% to $10.7 billion in 2025, then slipped by 1.75% to $10.5 billion in 2026.
  • Per Business Quant, the three latest BMY Cash & Current Investments figures stand at $10.5 billion (Q1 2026), $10.7 billion (Q4 2025), and $16.5 billion (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 5.28 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 22.05 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 9.39 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 5.70 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 12.04 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 7.64 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 13.08 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 10.49 Bn
10 Gsk 88.34 Bn 83.66 Bn - 4.68 Bn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 10.49 Bn
Dec 31, 2025 10.67 Bn
Sep 30, 2025 16.50 Bn
Jun 30, 2025 13.60 Bn
Mar 31, 2025 11.78 Bn
Dec 31, 2024 10.86 Bn
Sep 30, 2024 8.09 Bn
Jun 30, 2024 6.65 Bn
Mar 31, 2024 9.67 Bn
Dec 31, 2023 12.28 Bn
Sep 30, 2023 7.69 Bn
Jun 30, 2023 8.73 Bn
Mar 31, 2023 9.27 Bn
Dec 31, 2022 9.25 Bn
Sep 30, 2022 9.03 Bn
Jun 30, 2022 13.23 Bn
Mar 31, 2022 14.97 Bn
Dec 31, 2021 16.97 Bn
Sep 30, 2021 15.66 Bn
Jun 30, 2021 12.97 Bn
Mar 31, 2021 12.93 Bn
Dec 31, 2020 15.83 Bn
Sep 30, 2020 21.16 Bn
Jun 30, 2020 21.66 Bn
Mar 31, 2020 18.32 Bn
Dec 31, 2019 15.39 Bn
Sep 30, 2019 32.54 Bn
Jun 30, 2019 29.36 Bn
Mar 31, 2019 8.76 Bn
Dec 31, 2018 8.76 Bn
Sep 30, 2018 6.83 Bn
Jun 30, 2018 6.08 Bn
Mar 31, 2018 6.77 Bn
Dec 31, 2017 10.84 Bn
Sep 30, 2017 7.12 Bn
Jun 30, 2017 6.51 Bn
Mar 31, 2017 6.11 Bn
Dec 31, 2016 6.35 Bn
Sep 30, 2016 5.56 Bn
Jun 30, 2016 4.65 Bn
Mar 31, 2016 4.31 Bn
Dec 31, 2015 4.27 Bn
Sep 30, 2015 5.41 Bn
Jun 30, 2015 5.48 Bn
Mar 31, 2015 7.61 Bn
Dec 31, 2014 7.44 Bn
Sep 30, 2014 7.22 Bn
Jun 30, 2014 7.18 Bn
Mar 31, 2014 7.06 Bn
Dec 31, 2013 4.53 Bn
Sep 30, 2013 2.72 Bn
Jun 30, 2013 2.80 Bn
Mar 31, 2013 2.53 Bn
Dec 31, 2012 2.83 Bn
Sep 30, 2012 2.93 Bn
Jun 30, 2012 5.04 Bn
Mar 31, 2012 5.03 Bn
Dec 31, 2011 8.73 Bn
Sep 30, 2011 8.19 Bn
Jun 30, 2011 7.67 Bn
Mar 31, 2011 6.79 Bn
Dec 31, 2010 7.30 Bn
Sep 30, 2010 11.28 Bn
Jun 30, 2010 9.51 Bn
Mar 31, 2010 8.02 Bn
Dec 31, 2009 8.51 Bn
Sep 30, 2009 8.69 Bn
Jun 30, 2009 9.42 Bn
Mar 31, 2009 870.00 Mn